Premium
High‐throughput multiplex PCR genotyping for 35 red blood cell antigens in blood donors
Author(s) -
Jungbauer C.,
Hobel C. M.,
Schwartz D. W. M.,
Mayr W. R.
Publication year - 2012
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2011.01542.x
Subject(s) - genotyping , antigen , typing , multiplex , concordance , multiplex polymerase chain reaction , polymerase chain reaction , red blood cell , antibody , biology , whole blood , immunology , microbiology and biotechnology , virology , genotype , gene , genetics
Background and Objectives One to two per cent of patients in need of red cell transfusion carry irregular antibodies to red blood cell (RBC) antigens and have to be supplied with specially selected blood units. To be able to respond to those requests, blood centres have to screen a significant number of donors for a variety of antigens serologically, which is a costly and through the shortage of reagents, also limited procedure. To make this procedure more efficient, the Austrian Red Cross has developed a genotyping assay as an alternative approach for high throughput RBC typing. Materials and Methods A multiplex polymerase chain reaction (PCR) assay was designed for typing 35 RBC antigens in six reaction mixes. The assay includes both common as well as high‐frequency‐alleles: MNS1 , MNS2 , MNS3 and MNS4 ; LU1 , LU2 , LU8 and LU14 ; KEL1 , KEL2 , KEL3 , KEL4 , KEL6 , KEL7 , KEL11 , KEL17 and KEL21 ; FY1 , FY2 , FYB WK and FY0 (FYB ES ) ; JK1 and JK2 ; DI1 , DI2 , DI3 and DI4 ; YT1 and YT2 ; DO1 and DO2 ; CO1 and CO2 ; IN1 and IN2 . The assay was validated using 370 selected serologically typed samples. Subsequently 6000 individuals were screened to identify high frequency antigen (HFA)‐negative donors and to facilitate the search for compatible blood for alloimmunized patients. Results All controls showed complete concordance for the tested markers. The screening of 6000 donors revealed 57 new HFA‐negative donors and the blood group database was extended by approximately 210 000 results. Conclusion The study shows that in practice, this high‐throughput genotyping assay is feasible, fast and provides reliable results. Compared to serological testing, this molecular approach is also very cost‐efficient.